| Macaulay Ezera Nwojo, MD | |
|
8050 E Highway 191 Ste 250, Odessa, TX 79765-8613 | |
| (432) 558-7000 | |
| Not Available |
| Full Name | Macaulay Ezera Nwojo |
|---|---|
| Gender | Male |
| Speciality | Neurosurgery |
| Experience | 11 Years |
| Location | 8050 E Highway 191 Ste 250, Odessa, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1639433915 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207T00000X | Neurological Surgery | R74139 (Arizona) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Medical Center Hospital | Odessa, TX | Hospital |
| Midland Memorial Hospital | Midland, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Macaulay E Nwojo Md Pllc | 7416386370 | 4 |
News Archive
What are the cancer drugs of tomorrow and how will they be developed? At the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, researchers will present some answers to these and other pressing questions regarding emerging cancer therapeutics.
Researchers who simulated early stages of the SARS-CoV-2 outbreak in Wuhan, China, conclude that the virus was likely circulating earlier than has been described, possibly even in mid-October 2019.
This latest guidance sets out evidence based recommendations for clinicians prescribing synthetic, non-biologic, anti-rheumatic drugs to tackle multisystem rheumatic conditions.
Perelman School of Medicine researchers at the University of Pennsylvania report the first biomarker results reported from the Parkinson's Progression Markers Initiative (PPMI), showing that a comprehensive test of protein biomarkers in spinal fluid have prognostic and diagnostic value in early stages of Parkinson's disease.
› Verified 3 days ago
| Entity Name | Macaulay E Nwojo Md Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114565025 PECOS PAC ID: 7416386370 Enrollment ID: O20200330000309 |
News Archive
What are the cancer drugs of tomorrow and how will they be developed? At the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, researchers will present some answers to these and other pressing questions regarding emerging cancer therapeutics.
Researchers who simulated early stages of the SARS-CoV-2 outbreak in Wuhan, China, conclude that the virus was likely circulating earlier than has been described, possibly even in mid-October 2019.
This latest guidance sets out evidence based recommendations for clinicians prescribing synthetic, non-biologic, anti-rheumatic drugs to tackle multisystem rheumatic conditions.
Perelman School of Medicine researchers at the University of Pennsylvania report the first biomarker results reported from the Parkinson's Progression Markers Initiative (PPMI), showing that a comprehensive test of protein biomarkers in spinal fluid have prognostic and diagnostic value in early stages of Parkinson's disease.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Macaulay Ezera Nwojo, MD 8050 E Highway 191 Ste 250, Odessa, TX 79765-8613 Ph: (432) 558-7000 | Macaulay Ezera Nwojo, MD 8050 E Highway 191 Ste 250, Odessa, TX 79765-8613 Ph: (432) 558-7000 |
News Archive
What are the cancer drugs of tomorrow and how will they be developed? At the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, researchers will present some answers to these and other pressing questions regarding emerging cancer therapeutics.
Researchers who simulated early stages of the SARS-CoV-2 outbreak in Wuhan, China, conclude that the virus was likely circulating earlier than has been described, possibly even in mid-October 2019.
This latest guidance sets out evidence based recommendations for clinicians prescribing synthetic, non-biologic, anti-rheumatic drugs to tackle multisystem rheumatic conditions.
Perelman School of Medicine researchers at the University of Pennsylvania report the first biomarker results reported from the Parkinson's Progression Markers Initiative (PPMI), showing that a comprehensive test of protein biomarkers in spinal fluid have prognostic and diagnostic value in early stages of Parkinson's disease.
› Verified 3 days ago
Thomas D Meek, M.D. Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 511 N Alleghaney Ave, Odessa, TX 79761 Phone: 432-332-0478 Fax: 432-687-6298 | |
Alim Mirza Ladha, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 8050 E Highway 191, Ste 203, Odessa, TX 79765 Phone: 432-617-4551 Fax: 432-687-6298 | |
John Kyle Dorman, MD Neurological Surgery Medicare: May Accept Medicare Assignments Practice Location: 540 W 5th St Ste 320, Odessa, TX 79761 Phone: 432-580-4700 Fax: 432-332-2678 | |
Samantha Molinar Nunez, DNP, APRN, FNP-BC Neurological Surgery Medicare: Medicare Enrolled Practice Location: 8050 E Highway 191 Ste 250, Odessa, TX 79765 Phone: 432-558-7000 Fax: 432-214-2400 |